Beam Therapeutics Inc. (BEAM) Quick Ratio

Brandmark of Beam Tx (BEAM)

Beam Therapeutics Inc. (BEAM) relies on a unique patent perimeter for precision genome editing. The current ratio demonstrates present solvency, with the latest value recorded as 14.62. The company's financial status depends on external capital, as it lacks commercial products. The business is currently scaling clinical trials and expanding its own production capacities to implement point DNA modifications.

Beam Tx (BEAM) Quick Liquidity Indicator: for the period 07/04/2022 - 10/29/2026

beamtx.com - analytical breakdowns and key metrics (BEAM)

- share price and expert price forecast:
Stock Price Beam Therapeutics Corp|BEAM - Average Forecast Price
- market capitalization details:
Market Capitalization Beam Therapeutics Corp|BEAM - Enterprise Value
- balance sheet net asset value indicators:
Net Assets per Single Share Beam Therapeutics|BEAM - Company Net Assets|Market Cap to Net Assets Ratio beamtx.com|BEAM - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Equity Ratio Beam Therapeutics Inc.|BEAM - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Beam Therapeutics|BEAM - Aggregate Debt Obligations|Debts to Book Capitalization Beam Therapeutics Corp|BEAM - Long-Term Debt|Company Short-Term Debt Beam Therapeutics|Quick Ratio beamtx.com
- earnings and market multiples details:
BEAM - Net Profit
Summary company analytics:Beam Therapeutics Corp - BEAM
Finished products of beamtx.com

Assessing the fundamental risks of Beam Therapeutics Inc. (BEAM) requires an analysis of the company's ability to cover short-term obligations excluding slow-moving inventories. The current quick ratio of 14.62 reflects the volume of liquid assets and accounts receivable necessary to fund costly developments in precision DNA base editing without the urgent need to raise external capital.

Analysis of competing companies

TEM: Quick Ratio|Immediate Liquidity Qiagen Corp (QGEN)|IONS (Ionis Pharmaceuticals) - Quick Ratio|Quick Ratio repligen.com|Quick Liquidity Avidity Biosciences, Inc. (RNA)|Quick Liquidity Indicator CRISPR Therapeutics Inc CRSP|Sema4 - Quick Liquidity Indicator|Intermediate Coverage Ratio RARE|SRPT: Quick Liquidity Indicator|twistbioscience.com - Intermediate Liquidity Ratio|TXG: Quick Ratio|Intellia Therapeutics Inc - Intermediate Coverage Ratio|STOK (Stoke) - Quick Ratio|Immediate Liquidity BioLife BLFS|Quick Liquidity Wave Life Sciences (WVE)|MAZE (mazetx.com) - Intermediate Coverage Ratio|Quick Ratio SION (Sionna Therapeutics)|Quick Ratio Prime Medicine Inc PRME|TSHA - Quick Liquidity|Critical Liquidity Ratio QURE|MGTX: Quick Ratio|Immediate Liquidity regenxbio.com (RGNX)|Quick Liquidity Indicator SLDB|Quick Ratio Ocugen Inc|Quick Liquidity Indicator PACB (Pacific Biosciences of California)|Intermediate Liquidity Ratio BNTC|Quick Ratio DSGN (Design Therapeutics)|Interim Coverage Ratio rocketpharma.com (RCKT)|4D Molecular Therapeutics, Inc. - Quick Ratio|Lexeo Therapeutics (LXEO) - Quick Liquidity Indicator|korrobio.com (KRRO) - Quick Liquidity|EDIT - Interim Coverage Ratio|Quick Liquidity Indicator SLN|PRQR: Intermediate Coverage Ratio|Quick Ratio CDXS|Interim Coverage Ratio Sangamo Therapeutics Inc.|Quick Liquidity Nautilus Bio NAUT|MGX: Immediate Liquidity Ratio|Precision BioSciences, Inc. - Quick Ratio|Generation Bio Co. (GBIO) - Quick Liquidity Indicator|BOLD (Boundless Bio) - Quick Liquidity Indicator|XCUR - Interim Coverage Ratio|IMNN (Imunon Inc) - Quick Ratio|Quick Liquidity PHIO|Quick Ratio MBIO|RNAZ - Immediate Liquidity|Quick Ratio BNGO (Bionano Genomics)|Quick Ratio Applied DNA Sciences Inc APDN|BLUE - Quick Liquidity|ImmunoPrecise Antibodies (IPA) - Quick Liquidity Indicator|OMGA: Quick Ratio|Immediate Liquidity Ratio OMIC|Quick Liquidity Regulus Therapeutics Inc.|Immediate Liquidity Ratio SYRS (Syros Pharmaceuticals Inc.)|Quick Ratio TBIO|Quick Ratio TRACON Pharmaceuticals, Inc (TCON)|Quick Ratio UBX (Unity Biotechnology)